SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-058187
Filing Date
2024-05-13
Accepted
2024-05-13 07:05:11
Documents
13
Period of Report
2024-05-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fulc-20240511.htm   iXBRL 8-K 48792
2 EX-99.1 fulc-ex99_1.htm EX-99.1 81828
3 GRAPHIC img189780767_0.jpg GRAPHIC 2996
  Complete submission text file 0000950170-24-058187.txt   266881

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20240511.xsd EX-101.SCH 25998
16 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20240511_htm.xml XML 4925
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 24936843
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)